Novel compounds demonstrate potential in improving symptoms of depression and anxiety, indicating therapeutic promise.
Provided herein are novel nonhallucinogenic compounds as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in treating mental health disorders, namely depression, anxiety, stress disorders and eating disorders, and processes for preparing such compounds.
No takes yet. Share an insight, caveat, or question.
Ram W. Sabnis (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: